Adjuvants, Immunologic

"Adjuvants, Immunologic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Descriptor ID	D000276
MeSH Number(s)	D27.505.696.477.067
Concept/Terms	Adjuvants, Immunologic Adjuvants, Immunologic Immunostimulants Adjuvant, Immunologic Immunologic Adjuvant Immunological Adjuvant Adjuvant, Immunological Immunoactivators Immunoadjuvants Immunologic Adjuvants Immunopotentiators Adjuvants, Immunological Immunological Adjuvants

Below are MeSH descriptors whose meaning is more general than "Adjuvants, Immunologic".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Immunologic Factors [D27.505.696.477]
Adjuvants, Immunologic [D27.505.696.477.067]

Below are MeSH descriptors whose meaning is related to "Adjuvants, Immunologic".

Below are MeSH descriptors whose meaning is more specific than "Adjuvants, Immunologic".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Adjuvants, Immunologic" by people in this website by year, and whether "Adjuvants, Immunologic" was a major or minor topic of these publications.

Bar chart showing 56 publications over 24 distinct years, with a maximum of 6 publications in 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	1	0	1
2000	1	1	2
2001	1	2	3
2002	0	3	3
2003	2	0	2
2004	1	1	2
2006	2	0	2
2008	2	1	3
2009	1	1	2
2010	2	1	3
2011	2	3	5
2012	2	1	3
2013	0	1	1
2014	0	1	1
2015	2	0	2
2016	2	1	3
2017	1	0	1
2018	0	1	1
2019	0	2	2
2020	1	1	2
2021	0	3	3
2022	0	1	1
2023	0	2	2
2024	3	3	6

Below are the most recent publications written about "Adjuvants, Immunologic" by people in Profiles.

Alugupalli KR. Characterization of Turbo, a TLR Ligand-based Adjuvant for Glycoconjugate Vaccines. Immunohorizons. 2024 08 01; 8(8):527-537.

View in: PubMed
Alugupalli KR. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines. Front Immunol. 2024; 15:1383476.

View in: PubMed
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 07; 212(1):74-86.

View in: PubMed
Alugupalli KR. Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines. Immunohorizons. 2024 04 01; 8(4):317-325.

View in: PubMed
Moussa M, Abou Chakra M, Shore ND, Papatsoris A, Farahat Y, O'Donnell MA. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists. Arch Ital Urol Androl. 2024 Mar 19; 96(1):12244.

View in: PubMed
Alugupalli KR. TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity. Immunohorizons. 2024 01 01; 8(1):29-34.

View in: PubMed
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.

View in: PubMed
Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Comp?rat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 12 10; 41(35):5437-5447.

View in: PubMed
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.

View in: PubMed
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Yl?-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement